Abstract library

101 results for "economic burden".
#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof.Dr.Dr. Eva Caroline Winkler
#2713 The Economic Impact to Patients with Neuroendocrine Tumours
Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Assoc Prof David Wyld
Authors: Wyld D, Elliott T, Wakelin K, Leyden S, ...
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#1276 Caregivers’ Burden of Patients with Neuroendocrine Tumor and Related Factors
Introduction: Rare and increasing rapidly,patients with NETs have got more and more attention.With so many unknown and the long course of the disease, the caregaviers should bear a long and huge burden.However, the relative reviews are rare.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Liyan Zhang
Authors: Zhang L, ...
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements
Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Keywords: PET burden
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran